IP Library Granted Patent US 8,354,116
Granted Patent B2
US 8,354,116 · App. 11/820,172 · Granted Jan 15, 2013

Bifunctional synthetic molecules

Inventors: Stephen G. Carter (Andover, MA); Kanu Patel (Londonderry, NH); Zhen Zhu (Tewksbury, MA); Lixin Qiao (Tewksbury, MA)
Assignee: BioChemics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,354,116
App. No.
11/820,172
Granted
Jan 15, 2013
Kind
B2
Abstract

The synthesis and use of bifunctional molecules to improve the topical and transdermal delivery efficiency of various types of therapeutic agents or agents designed to promote the transdermal delivery of those therapeutic agents either into the skin tissue or into the systemic circulation. Three major classes of molecules are covalently joined as bifunctional substances; chemical vasodilators, passive dermal penetration enhancers and therapeutic or diagnostic drugs. Chemical vasodilators may be delivered into the skin to increasing the blood flow in a tissue that has compromised circulation or they may be used as part of a delivery vehicle to promote the delivery of the drug. Passive dermal penetration enhancers are those chemicals that promote the passive penetration of drugs and other chemicals through the stratum corneum and epidermis of the skin tissue. Drugs and diagnostic agents are the third group of chemicals that are candidates for the linkage of molecules.

Claims (13)

1. A method for the preparation of a bifunctional functioning molecule, comprising providing a first molecule having one of vasodilatory or dermal penetration enhancing properties that has a first reactive group in the molecule selected from the group consisting of an amine, an alcohol, a carboxylic acid functional group, and a hydroxyl group, and reacting said first molecule with a second molecule having the other of vasodilatory or dermal penetration enhancing properties that has a second reactive group in the molecule reactive with said first reactive group, said second reactive group being selected from the group consisting of an amine, an alcohol, a carboxylic acid functional group, and a hydroxyl group.

2. A bifunctional molecule comprising

a. a vasodilator selected from the group consisting of amrinone, arginine, bamethan sulphate, bencyclane fumarate, benfurodil hemisuccinate, benzyl nicotinate, buflomedil hydrochloride, buphenine hydrochloride, butalamine hydrochloride, cetiedil citrate, ciclonicate, cinepazide maleate, cyclandelate, di-isopropylammonium dichloroacetate, ethyl nicotinate, hepronicate, hexyl nicotinate, ifenprodil tartrate, inositol nicotinate, isoxsuprine hydrochloride, kallidinogenase, methyl nicotinate, naftidrofuryl oxalate, nicametate citrate, niceritrol, nicoboxil, nicofuranose, nicotinyl alcohol, nicotinyl alcohol tartrate, nitric oxide, nonivamide, oxpentifylline, papaverine, papaveroline, pentifylline, peroxynitrite, pinacidil, pipratecol, propentofyltine, raubasine, suloctidil, teasuprine, thymoxamine hydrochloride, tocopherol nicotinate, tolazoline, xanthinol nicotinate, diazoxide, hydralazine, minoxidil, sodium nitroprusside, clonidine, quanaberz, methyl dopa, indoramin, phenoxybenzamine, phentolamine, prazosin, bedmidine, debrisoquine, guanethidine, benazepril, captopril, cilazapril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, pentolinium, trimetaphan, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, verapamil, prostacyclin, thrombuxane A2, leukotrienes, PGA, PGA1, PGA2, PGE1, PGE2, PGD, PGG, PGH, saralasin, nitroglycerin, labetalol, thrazide, isosorbide dinitrate, pentaerythritol tetranitrate, digitalis, hydralazine, diazoxide, and sodium nitroprusside;

b. a dermal penetration enhancer selected from the group consisting of linoleic acids, linolenic acids, oleic acids, stearic acids, and myristic acids; sodium laurate, sodium lauryl sulfate, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, cholesterol, m-pyrrole, dimethyl acetamide, limonene, menthol, salicylic acid, citric acid, succininc acid, decyl methyl sulfoxide, urea, peanut oil, hemp, borage, olive oil, sunflower oil, soybean oil, monoi oil and macadamia oil;

wherein said vasodilator and said dermal penetration enhancer are covalently linked.

3. A bifunctional molecule comprising

a. a vasodilator selected from the group consisting of amrinone, arginine, bamethan sulphate, bencyclane fumarate, benfurodil hemisuccinate, benzyl nicotinate, buflomedil hydrochloride, buphenine hydrochloride, butalamine hydrochloride, cetiedil citrate, ciclonicate, cinepazide maleate, cyclandelate, di-isopropylammonium dichloroacetate, ethyl nicotinate, hepronicate, hexyl nicotinate, ifenprodil tartrate, inositol nicotinate, isoxsuprine hydrochloride, kallidinogenase, methyl nicotinate, naftidrofuryl oxalate, nicametate citrate, niceritrol, nicoboxil, nicofuranose, nicotinyl alcohol, nicotinyl alcohol tartrate, nitric oxide, nonivamide, oxpentifylline, papaverine, papaveroline, pentifylline, peroxynitrite, pinacidil, pipratecol, propentofyltine, raubasine, suloctidil, teasuprine, thymoxamine hydrochloride, tocopherol nicotinate, tolazoline, xanthinol nicotinate, diazoxide, hydralazine, minoxidil, sodium nitroprusside, clonidine, quanaberz, methyl dopa, indoramin, phenoxybenzamine, phentolamine, prazosin, bedmidine, debrisoquine, guanethidine, benazepril, captopril, cilazapril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, pentolinium, trimetaphan, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, verapamil, prostacyclin, thrombuxane A2, leukotrienes, PGA, PGA1, PGA2, PGE1, PGE2, PGD, PGG, PGH, saralasin, nitroglycerin, labetalol, thrazide, isosorbide dinitrate, pentaerythritol tetranitrate, digitalis, hydralazine, diazoxide, and sodium nitroprusside;

b. an active drug molecule selected from the group consisting of acetaminophen, acetohydoxamic acid, acetophenazine, acyclovir, albuterol, allopurinol, amiloride, amoxicillin, amphetamine, ampicillin, atenolol, baclofen, beclomethasone, betamethasone, budesonide, bumetanide, butorphanol, carbamazepine, carphenazine, cefuroxime, cephradine, chloramphenicol, chlorothiazide, chlorzoxazone, cinoxacin, clorazepate, cloxacillin, cyclacillin, dapsone, dicloxacillin, diethylstilbestrol, dopamine, doxorubicin, estradiol, fenoprofen, human growth hormone, hydralazine, hydrochlorothiazide, ibuprofen, indomethacin, insulin, isoproterenol, levodopa, levothyroxine, meclofenamate, melphalan, metformin methyl salicylate, metronidazole, minoxidil, morphine, nadolol, nalidixic acid, naproxen, nomifensine, norfloxacin, oxaprozin, paramethasone, perphenazine, phenylpropanolamine, probenecid, quinethazone, ritodrine, scopolamine, serotonin, terbutaline, terfenadine, tocainide, triamterine, trimethoprim, and valacyclovir;

wherein said vasodilator and said active drug molecule are covalently linked.

4. A bifunctional molecule comprising

c. a. a dermal penetration enhancer selected from the group consisting of linoleic acids, linolenic acids, oleic acids, stearic acids, and myristic acids; sodium laurate, sodium lauryl sulfate, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, cholesterol, m-pyrrole, dimethyl acetamide, limonene, menthol, salicylic acid, citric acid, succininc acid, decyl methyl sulfoxide, urea, peanut oil, hemp, borage, olive oil, sunflower oil, soybean oil, monoi oil and macadamia oil;

b. an active drug molecule selected from the group consisting of acetaminophen, acetohydoxamic acid, acetophenazine, acyclovir, albuterol, allopurinol, amiloride, amoxicillin, amphetamine, ampicillin, atenolol, baclofen, beclomethasone, betamethasone, budesonide, bumetanide, butorphanol, carbamazepine, carphenazine, cefuroxime, cephradine, chloramphenicol, chlorothiazide, chlorzoxazone, cinoxacin, clorazepate, cloxacillin, cyclacillin, dapsone, dicloxacillin, diethylstilbestrol, dopamine, doxorubicin, erythropoietic, estradiol, fenoprofen, human growth hormone, hydralazine, hydrochlorothiazide, ibuprofen, indomethacin, insulin, isoproterenol, levodopa, levothyroxine, meclofenamate, melphalan, metformin methyl salicylate, metronidazole, minoxidil, morphine, nadolol, nalidixic acid, naproxen, nomifensine, norfloxacin, oxaprozin, paramethasone, perphenazine, phenylpropanolamine, probenecid, quinethazone, ritodrine, scopolamine, serotonin, terbutaline, terfenadine, tocainide, triamterine, trimethoprim, and valacyclovir;

wherein said dermal penetration enhancer and said active drug molecule are covalently linked.

Assignments (5)
PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT Recorded Dec 20, 2016
From: INPELLIS, INC.
To: ADEC PRIVATE EQUITY INVESTMENTS, LLC
Reel/Frame 041034/0789 →
PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT Recorded Dec 8, 2016
From: INPELLIS, INC., AS SUCCESSOR/ASSIGNEE OF BIOCHEMICS, INC. BY INTELLECTUAL PROPERTY PURCHASE AGREEMENT DATED OCTOBER 24, 2015
To: ADEC PRIVATE EQUITY INVESTMENTS, LLC, AS COLLATERAL AGENT
Reel/Frame 040854/0170 →
SECURITY INTEREST Recorded Jun 5, 2014
From: BIOCHEMICS, INC.
To: BIO STRATEGIES, LP
Reel/Frame 033086/0888 →
SECURITY INTEREST Recorded May 21, 2014
From: BIOCHEMICS, INC.
To: MSCISZ, CHESTER AND CAROL; JMS SYLVAN REALTY TRUST; PERRY REALTY TRUST; MSCISZ NOMINEE TRUST; ENDICOTT REALTY TRUST; DANVERSPORT LIMITED PARTNERSHIP
Reel/Frame 032939/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2007
From: CARTER, STEPHEN G.; PATEL, KANU; ZHU, ZHEN; QIAO, LIXIN
To: BIOCHEMICS, INC.
Reel/Frame 019985/0460 →
Continuity (1)
Related Publication 20080312296A1 · Dec 18, 2008